Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

NCT02601209 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02601209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02601209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2015
Completion date
July 11, 2022
Enrollment
151 (actual)
Sites
460

Conditions

As the registry lists them; a condition with its own page is linked.

high grade sarcoma, metastatic leiomyosarcoma, metastatic malignant peripheral nerve sheath tumor, metastatic synovial sarcoma, metastatic undifferentiated pleomorphic sarcoma, metastatic unresectable sarcoma, myxofibrosarcoma, recurrent leiomyosarcoma, recurrent malignant peripheral nerve sheath tumor, recurrent synovial sarcoma, recurrent undifferentiated pleomorphic sarcoma, stage iii uterine corpus leiomyosarcoma ajcc v8, stage iiia uterine corpus leiomyosarcoma ajcc v8, stage iiib uterine corpus leiomyosarcoma ajcc v8, stage iiic uterine corpus leiomyosarcoma ajcc v8, stage iv uterine corpus leiomyosarcoma ajcc v8, stage iva uterine corpus leiomyosarcoma ajcc v8, stage ivb uterine corpus leiomyosarcoma ajcc v8, unresectable leiomyosarcoma